Product nameAnti-C9 antibody
See all C9 primary antibodies
DescriptionRabbit polyclonal to C9
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Synthetic peptide corresponding to Human C9 aa 500 to the C-terminus (C terminal) conjugated to keyhole limpet haemocyanin.
(Peptide available as
- Recombinant Human C9 protein (ab114199) can be used as a positive control in WB. This antibody gave a positive signal in the following tissue lysates: Human placenta; Human plasma total protein
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 1% BSA, PBS. pH 7.4
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab67040 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionConstituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC.
Involvement in diseaseDefects in C9 are a cause of complement component 9 deficiency (C9D) [MIM:613825]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis.
Sequence similaritiesBelongs to the complement C6/C7/C8/C9 family.
Contains 1 EGF-like domain.
Contains 1 LDL-receptor class A domain.
Contains 1 MACPF domain.
Contains 1 TSP type-1 domain.
modificationsThrombin cleaves factor C9 to produce C9a and C9b.
Phosphorylation sites are present in the extracelllular medium.
Cellular localizationSecreted. Cell membrane. Secreted as soluble monomer. Oligomerizes at target membranes, forming a pre-pore. A conformation change then leads to the formation of a 100 Angstrom diameter pore.
- Information by UniProt
- ARMD15 antibody
- C9 antibody
- C9 deficiency antibody
All lanes : Anti-C9 antibody (ab67040) at 1 µg/ml
Lane 1 : Human Plasma Total Protein Lysate
Lane 2 : Human placenta tissue lysate - total protein (ab29745)
Lysates/proteins at 10 µg per lane.
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 63 kDa
Observed band size: 74 kDa why is the actual band size different from the predicted?
Additional bands at: 40 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 16 minutes
Human Complement component C9 precursor contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted. The 74 kDa band observed is also comparable to the molecular weight seen with other commercially available antibodies to C9.
ab67040 has not yet been referenced specifically in any publications.